Tarsus Pharmaceuticals, Inc. (TARS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 02/17/26
Down 16.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Tarsus Pharmaceuticals (TARS)Zacks Investment Research • 01/26/26
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Beats Revenue EstimatesZacks Investment Research • 11/04/25
Tarsus Reports Third Quarter 2025 Financial Results and Recent Business AchievementsGlobeNewsWire • 11/04/25
Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025GlobeNewsWire • 10/28/25
Tarsus Pharmaceuticals (TARS) Moves 10.9% Higher: Will This Strength Last?Zacks Investment Research • 10/06/25
Lyme Disease Is Spiking. This Biotech Nears A Treatment And A Buy Point.Investors Business Daily • 08/14/25
Tarsus Reports Second Quarter 2025 Financial Results and Recent Business AchievementsGlobeNewsWire • 08/06/25
Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025GlobeNewsWire • 07/30/25
Tarsus Pharmaceuticals (TARS) Loses -15.59% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 05/14/25
Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt PaydownPRNewsWire • 05/05/25
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/01/25
Tarsus Reports First Quarter 2025 Financial Results and Recent Business AchievementsGlobeNewsWire • 05/01/25
Wall Street Analysts See a 31.89% Upside in Tarsus Pharmaceuticals (TARS): Can the Stock Really Move This High?Zacks Investment Research • 04/30/25
Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025GlobeNewsWire • 04/24/25